Clinical Genomics, CSIRO settle on licence terms
Clinical Genomics and the CSIRO have signed a licensing agreement to allow the former to develop a blood test for bowel cancer.
The pair have signed a licence agreement based on patented and jointly discovered biomarkers for colorectal cancer.
The global agreement will allow Clinical Genomics to develop and promote the ColoVantage Plasma test.
The test screens for genes with cancer-specific signatures that can be detected in the blood of many patients with early-stage bowel cancer. It is designed as an alternative for patients who can’t and won’t undergo the current faecal occult bowel screening standard.
Clinical Genomics and the CSIRO have been collaborating on R&D focused on identifying and testing biomarkers for bowel tumour DNA, and the licensing deal is the culmination of this project.
“We’re pleased to achieve this collaborative research milestone with CSIRO and we are now set to make a contribution to bowel cancer screening in the real world,” Clinical Genomics CEO Dr Larry LaPointe said.
“We’ve already run a local pilot of the blood test here in NSW and the clinical testing around the patent-pending technology is encouraging.”
He said the company’s ultimate aim is to have ColoVantage Plasma integrated into protocols for bowel cancer screening around the world.
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
